• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Flexion reports data from Phase II bilateral osteoarthritis trial

October 22, 2018 By Sarah Faulkner

Flexion Therapeutics - updated logoFlexion Therapeutics (NSDQ:FLXN) touted data today from a Phase II trial assessing the bilateral dosing of its extended-release triamcinolone acetonide injection in people with bilateral osteoarthritis.

The study found that bilateral injections of Flexion’s Zilretta therapy resulted in lower plasma concentrations of triamcinolone acetonide compared to immediate-release triamcinolone acetonide in crystalline suspension (TAcs). The company also noted that concurrent administration of Zilretta was well tolerated among the study’s participants.

The 24-patient Phase II study randomized participants to receive concurrent doses of either Zilretta or TAcs in both knees. The most common treatment-emergent adverse event in people given Zilretta was injection site pain, Flexion reported. In people treated with TAcs, the most common adverse events were arthralgia and joint swelling.

“Typically, physicians do not treat OA with corticosteroid injections in both knees at the same time due to concerns about potential systemic overexposure, which may require patients to return at a separate office visit to receive treatment in the second knee,” Dr. Scott Kelley, Flexion’s chief medical officer, said in prepared remarks.

“These results suggest that the extended-release formulation of Zilretta may result in substantially lower systemic concentrations of triamcinolone acetonide following bilateral injections compared to traditional immediate-release steroids. The findings add to the robust and growing body of data that has been generated to provide clinicians with a deeper understanding of Zilretta’s clinical profile,” Kelley added.

FLXN shares were trading at $17.08 apiece in mid-morning activity today, down -9.9%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Orthopedics, Wall Street Beat Tagged With: Flexion Therapeutics

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Reader Interactions

Comments

  1. Joe Koontz says

    October 22, 2018 at 1:24 pm

    That all seems like relatively good news but I seem to be missing something based on the stock price. Can anyone offer some insight? Thanks…

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS